# Evaluation of (Doravirine / Lamivudine / Tenofovir Disoproxil Fumarate) (Delstrigo®) as a New Strategy for Non-occupational Post Exposure Prophylaxis, a Prospective Open Label Study

> **NCT04233372** · PHASE4 · COMPLETED · sponsor: **Hospital Clinic of Barcelona** · enrollment: 399 (actual)

## Conditions studied

- Hiv

## Interventions

- **DRUG:** Delstrigo

## Key facts

- **NCT ID:** NCT04233372
- **Lead sponsor:** Hospital Clinic of Barcelona
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-08-27
- **Primary completion:** 2022-07-28
- **Final completion:** 2022-07-28
- **Target enrollment:** 399 (ACTUAL)
- **Last updated:** 2025-09-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04233372

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04233372, "Evaluation of (Doravirine / Lamivudine / Tenofovir Disoproxil Fumarate) (Delstrigo®) as a New Strategy for Non-occupational Post Exposure Prophylaxis, a Prospective Open Label Study". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04233372. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*